Pure Global

Study to evaluate the efficacy, safety and immunogenicity of two or three doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants. - Trial 2015-001485-26

Access comprehensive clinical trial information for 2015-001485-26 through Pure Global AI's free database. This phase not specified trial is sponsored by GlaxoSmithKline Biologicals and is currently status unknown. The study focuses on Healthy volunteers.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
2015-001485-26
Trial Details
EU Clinical Trials Register • 2015-001485-26
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Study to evaluate the efficacy, safety and immunogenicity of two or three doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants.

Study Focus

Healthy volunteers

Sponsor & Location

GlaxoSmithKline Biologicals

Timeline & Enrollment

N/A

N/A

N/A

Primary Outcome

Occurrence of severe RV GE (score > 11 on a 20-point Vesikari scoring system caused by the circulating wild-type RV strains in pooled HRV groups versus the placebo group.

ICD-10 Classifications

Healthy person accompanying sick person
Routine general health check-up of armed forces
Routine general health check-up of sports teams
Routine general health check-up of inhabitants of institutions

Data Source

EU Clinical Trials Register

2015-001485-26

Non-Device Trial